Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 17/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3454184 | 1.00 | FYN (0.52) | FYNMKNK1HCAR3HDAC1 | |
| SCHEMBL13110819 | 0.92 | FYN (0.56) | FYNMKNK1 | |
| Fumaric Acid SCHEMBL3452553 | 0.89 | FYN (0.61) | FYNMKNK1 | |
| Fumaric Acid SCHEMBL3452560 | 0.89 | FYN (0.61) | FYNMKNK1 | |
| SCHEMBL13110974 | 0.87 | FYN (0.55) | FYNMKNK1 | |
| Fumaric Acid SCHEMBL3454016 | 0.87 | FYN (0.52) | FYNMKNK1 | |
| Hydrochloric Acid SCHEMBL3452311 | 0.86 | FYN (0.54) | FYNMKNK1 | |
| Hydrochloric Acid SCHEMBL3452316 | 0.86 | FYN (0.54) | FYNMKNK1 | |
| SCHEMBL3452669 | 0.83 | FYN (0.55) | FYNMKNK1HCAR3 | |
| SCHEMBL3452667 | 0.83 | FYN (0.55) | FYNMKNK1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820670-B2 | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | ALCON RESEARCH, LTD. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON MANUFACTURING, LTD. (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOT2 | FYN 856/4885MKNK1 342/4885HCAR3 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.